Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Rev Clin Esp (Barc) ; 223(8): 486-492, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37532015

RESUMEN

BACKGROUND AND OBJECTIVE: There are limited studies analyzing hypercalcemia in hospitalized patients. Our objectives were to describe the clinical characteristics of hospitalized patients with hypercalcemia, estimate its prevalence in the hospital setting, analyze the rate of correction of hypercalcemia, and identify prognostic variables. MATERIALS AND METHODS: Observational, longitudinal, retrospective, and bicentric study. Adult patients admitted to two hospitals in Málaga (2014-2018) with a diagnosis of hypercalcemia were included. The minimum follow-up was 2 years or until death. RESULTS: A total of 205 patients with hypercalcemia were included (incidence: 0.13%). The mean age (SD) was 68.2 (13.1) years, with a predominance of males (55.1%). The median (IQR) serum calcium at admission was 13.1 (11.8-14.6) mg/dl. The most common etiologies were neoplasms (75.1%), primary hyperparathyroidism, and medications (both 8.8%). The median (IQR) follow-up period was 5.1 (1.7-60.3) weeks. The most commonly used treatments were fluid therapy (86.8%), loop diuretics (70.9%), bisphosphonates (60.7%), and glucocorticoids (46.2%). The rate of correction of hypercalcemia was 65.2%, with a median (IQR) of 6 (3-10) days. The mortality rate was 81.5%. The median (95% CI) survival was 5.1 (3-7.3) weeks. Factors associated with higher mortality were advanced age, neoplastic etiology, serum calcium at admission, and failure to correct hypercalcemia. CONCLUSIONS: Hypercalcemia in hospitalized patients is mainly due to neoplastic processes and is associated with high mortality. We observed a low rate of adherence to recommendations for the management of hypercalcemia.


Asunto(s)
Hipercalcemia , Neoplasias , Adulto , Masculino , Humanos , Anciano , Femenino , Hipercalcemia/epidemiología , Hipercalcemia/etiología , Hipercalcemia/terapia , Calcio/uso terapéutico , Estudios Retrospectivos , Neoplasias/complicaciones , Neoplasias/epidemiología , Pronóstico
2.
Rev Clin Esp ; 211 Suppl 1: 2-7, 2011 Mar.
Artículo en Español | MEDLINE | ID: mdl-21458642

RESUMEN

The population aged 65 years or more is set to increase in the next few years, especially in Spain and elsewhere in Europe. Cardiovascular diseases (CVD) are the main cause of morbidity and mortality worldwide as well as in Spain. Most studies on vascular risk factors (VRF) have been performed in younger persons, usually aged less than 70 years and without associated pathologic conditions. Patients with pluripathologies are those with multiple chronic diseases and advanced age (a mean of 78 years) in whom the most significant diseases are cardiovascular, with several VRF, leading to high mortality. Strategies to reduce morbidity and mortality in this age group are required.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Anciano , Enfermedades Cardiovasculares/etiología , Humanos , Factores de Riesgo , España
3.
Rev Clin Esp (Barc) ; 223(2): 98-99, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36669739
4.
Rev Clin Esp (Barc) ; 223(1): 65, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36341989
5.
Rev Clin Esp (Barc) ; 217(4): 229-237, 2017 May.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28245907

RESUMEN

Improvements in living conditions and scientific advances have led to an unprecedented demographic change. The curing of numerous acute diseases and the growing adoption of unhealthy lifestyles have caused a pandemic of cumulative chronic diseases that constitute the leading cause of death worldwide. Currently, the most common situation is the coexistence of multiple chronic diseases (or polypathology). This situation undermines socio-economic development and increases inequality. This results in an overriding need to change the way in which health and disease are addressed. Healthcare systems are not prepared to meet the needs of complex polypathological patients. In this article, we summarise the challenges facing healthcare systems and states, as well as the main recommendations from the organisations responsible for healthcare.

6.
Rev Clin Esp (Barc) ; 221(10): 598-599, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34509419

Asunto(s)
Medicina , Humanos
7.
Rev. clín. esp. (Ed. impr.) ; 223(8): 486-492, oct. 2023. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-225874

RESUMEN

Antecedentes y objetivo Existen escasos estudios que analicen la hipercalcemia en pacientes hospitalizados. Nuestros objetivos fueron: describir las características clínicas de los pacientes hospitalizados con hipercalcemia, estimar su prevalencia en el medio hospitalario, analizar la tasa de corrección de la hipercalcemia, e identificar variables pronósticas. Materiales y métodos Estudio observacional, longitudinal, retrospectivo y bicéntrico. Se incluyeron pacientes adultos ingresados en dos hospitales de Málaga (2014-2018) con diagnóstico de hipercalcemia. El seguimiento mínimo fue de 2años o hasta el fallecimiento. Resultados Se incluyeron 205 pacientes con hipercalcemia (incidencia: 0,13%). La edad media (DE) fue de 68,2 (13,1) años, con predominio de varones (55,1%). La calcemia mediana (RIC) al ingreso fue de 13,1 (11,8-14,6) mg/dL. Las etiologías más frecuentes fueron: neoplasias (75,1%), hiperparatiroidismo primario y fármacos (ambas, 8,8%). La mediana (RIC) de seguimiento fue de 5,1 (1,7-60,3) semanas. Los tratamientos más usados fueron: fluidoterapia (86,8%), diuréticos de asa (70,9%), bifosfonatos (60,7%) y glucocorticoides (46,2%). La tasa de corrección de la hipercalcemia fue del 65,2%, con una mediana (RIC) de 6 (3-10) días La tasa de mortalidad fue del 81,5%. La mediana (IC95%) de supervivencia fue de 5,1 (3-7,3) semanas. Los factores asociados a una mayor mortalidad fueron: edad avanzada, etiología neoplásica, calcemia al ingreso y no corrección de la hipercalcemia. Conclusiones La hipercalcemia en pacientes hospitalizados se debe principalmente a procesos neoplásicos y se asocia a una elevada mortalidad. Observamos una baja tasa de seguimiento de las recomendaciones para el manejo de la hipercalcemia (AU)


Background and objective There are limited studies analyzing hypercalcemia in hospitalized patients. Our objectives were to describe the clinical characteristics of hospitalized patients with hypercalcemia, estimate its prevalence in the hospital setting, analyze the rate of correction of hypercalcemia, and identify prognostic variables. Materials and methods Observational, longitudinal, retrospective, and bicentric study. Adult patients admitted to two hospitals in Málaga (2014-2018) with a diagnosis of hypercalcemia were included. The minimum follow-up was 2years or until death. Results A total of 205 patients with hypercalcemia were included (incidence: 0.13%). The mean age (SD) was 68.2 (13.1) years, with a predominance of males (55.1%). The median (IQR) serum calcium at admission was 13.1 (11.8-14.6) mg/dL. The most common etiologies were neoplasms (75.1%), primary hyperparathyroidism, and medications (both 8.8%). The median (IQR) follow-up period was 5.1 (1.7-60.3) weeks. The most commonly used treatments were fluid therapy (86.8%), loop diuretics (70.9%), bisphosphonates (60.7%), and glucocorticoids (46.2%). The rate of correction of hypercalcemia was 65.2%, with a median (IQR) of 6 (3-10) days. The mortality rate was 81.5%. The median (95%CI) survival was 5.1 (3-7.3) weeks. Factors associated with higher mortality were advanced age, neoplastic etiology, serum calcium at admission, and failure to correct hypercalcemia. Conclusions Hypercalcemia in hospitalized patients is mainly due to neoplastic processes and is associated with high mortality. We observed a low rate of adherence to recommendations for the management of hypercalcemia (AU)


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Hipercalcemia/epidemiología , Hospitalización/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Estudios de Seguimiento , Estudios Longitudinales , Estudios Retrospectivos , España/epidemiología , Incidencia
8.
Eur J Intern Med ; 23(2): e44-7, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22284255

RESUMEN

PURPOSE: To study the prevalence of vertebral fractures (VF), the associated risk factors and the degree of diagnosis and prescription upon discharge in a series of hospitalized medical patients ≥50 years of age. METHODS: A cross-sectional, multicentre and observational study in which a prevalence cut-off was carried out concerning patients admitted to six Internal Medicine departments in Malaga (Spain). The main variables were the existence of a fracture in the spine lateral x-ray, the inclusion of the diagnosis of a fracture in the discharge report, and the establishment of anti-osteoporotic treatment at discharge. RESULTS: 254 patients were included (mean age 66.4±14.9 years). The prevalence of VF was of 14.2% (36 cases). Patients with VF presented with a higher mean age, compared to those without VF (70.14 vs. 65.7 years) (p=0.035). The means contrast for the FRAX index variable (major osteoporotic and hip fracture), grouping according to the presence of VF, did not show any statistical significance (p=0.369 and p=0.788, respectively). Only in 8.3% of the discharge reports of patients with VF had the diagnosis of VF and/or osteoporosis been recorded and the prescription of anti-osteoporotic drugs been included. CONCLUSIONS: A high prevalence of asymptomatic VF is verified in medical inpatients ≥50 years of age. The FRAX index did not turn out to be predictive of the presence of VF in this population. There is an underdiagnosis of osteoporotic VF in the coding at hospital discharge. Action protocols are necessary to avoid clinical inactivity regarding this entity.


Asunto(s)
Hospitales Especializados/estadística & datos numéricos , Pacientes Internos/estadística & datos numéricos , Medicina Interna , Fracturas Osteoporóticas/epidemiología , Medición de Riesgo , Fracturas de la Columna Vertebral/epidemiología , Vértebras Torácicas/lesiones , Factores de Edad , Anciano , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fracturas Osteoporóticas/diagnóstico por imagen , Radiografía , Factores de Riesgo , España/epidemiología , Fracturas de la Columna Vertebral/diagnóstico por imagen
14.
15.
Rev. clín. esp. (Ed. impr.) ; 217(4): 229-237, mayo 2017. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-162414

RESUMEN

La mejoría de las condiciones de vida y los avances científicos han propiciado un cambio demográfico sin precedentes. La curación de muchas enfermedades agudas y la adopción creciente de estilos de vida no saludables han provocado una pandemia de enfermedades crónicas acumulativas que constituyen la primera causa de mortalidad mundial. Lo más frecuente, actualmente, es la coexistencia de múltiples enfermedades crónicas o pluripatología. Esta situación socava el desarrollo socioeconómico y aumenta las desigualdades. Ello condiciona una necesidad imperiosa de cambiar el modo de abordar la salud y la enfermedad. Los sistemas sanitarios no están preparados para satisfacer las necesidades de los pacientes pluripatológicos complejos. En el presente artículo se resumen los desafíos a los que se enfrentan los sistemas sanitarios y los propios estados, así como las principales recomendaciones de los organismos responsables de la salud de las personas (AU)


Improvements in living conditions and scientific advances have led to an unprecedented demographic change. The curing of numerous acute diseases and the growing adoption of unhealthy lifestyles have caused a pandemic of cumulative chronic diseases that constitute the leading cause of death worldwide. Currently, the most common situation is the coexistence of multiple chronic diseases (or polypathology). This situation undermines socio-economic development and increases inequality. This results in an overriding need to change the way in which health and disease are addressed. Healthcare systems are not prepared to meet the needs of complex polypathological patients. In this article, we summarise the challenges facing healthcare systems and states, as well as the main recommendations from the organisations responsible for healthcare (AU)


Asunto(s)
Humanos , Enfermedad Crónica/epidemiología , Grupo de Atención al Paciente/tendencias , Comorbilidad/tendencias , Atención Primaria de Salud/estadística & datos numéricos , Pautas de la Práctica en Medicina , Administración de los Servicios de Salud/tendencias , Dinámica Poblacional
17.
Lupus ; 13(12): 934-40, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15645749

RESUMEN

We evaluated the influence of the hereditary make-up on the development of systemic lupus erythematosus (SLE) in two ethnic groups [Gypsy and white Caucasian Mediterranean (WCM) populations], living in the same geographic area. We compared 81 WCM and 25 Gypsy patients with SLE. The control group consisted of 185 healthy unrelated individuals, 105 WC and 80 Gypsies. In the Gypsy population, the onset of SLE occurred at earlier ages than in the other ethnic group (25.9 versus 32.0 years, P = 0.02), and showed lower SLEDAI peak values (4.9 versus 7.0, P = 0.016). The frequency of joint, kidney, gastrointestinal and eye involvement was significantly lower in Gypsy patients. In contrast, SLE-associated antiphospholipid syndrome, thrombosis and livedo reticularis were more frequent in Gypsies than in the majority ethnic group (WCM). In WCM patients, DRB1* 1303-DQB1*0301 haplotype was associated with SLE (P = 0.001, Pc = 0.038). We found SLE to be associated with DR5 (P = 0.006, Pc = 0.05) in the Gypsy population as well as a protective effect of DPB1*0401 when DR5 was not present (P = 0.008, Pc = 0.032). In conclusion, we found some clinical differences between WCM and Gypsy patients with SLE. Furthermore, HLA associations between HLA-DRB1-DQB1 and SLE were different for Gypsy people.


Asunto(s)
Antígenos HLA-DP/genética , Antígenos HLA-DQ/genética , Antígenos HLA-DR/genética , Lupus Eritematoso Sistémico/etnología , Romaní/genética , Población Blanca/genética , Adulto , Femenino , Cadenas beta de HLA-DP , Cadenas beta de HLA-DQ , Cadenas HLA-DRB1 , Humanos , Lupus Eritematoso Sistémico/etiología , Masculino , Región Mediterránea/etnología , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , España
18.
Rev Clin Esp ; 199(2): 59-65, 1999 Feb.
Artículo en Español | MEDLINE | ID: mdl-10216395

RESUMEN

OBJECTIVE: To report the variability in antibiotic prescribing habits for patients diagnosed of non-specified acute respiratory infections (ARI) (according to the International Classification of Diseases 9MC) at Emergency Departments of ten Spanish hospitals, and to evaluate the appropriateness of antimicrobial prescription for such patients, after specifically elaborating some reference patterns for appropriate antimicrobial use. DESIGN: Descriptive study of variability in clinical practice by means of a prospective series of cases. Study of appropriateness by means of elaborating reference standards for appropriate use and comparison with the data from the descriptive study with such standards. DURATION: six months. SETTING: Emergency Department in ten Spanish hospitals from different autonomic communities: Andalucía, Islas Canarias, Castilla-León, Cataluña, Galicia, Madrid, Murcia and Valencia for a 6-month period. PATIENTS: Patients with the diagnosis of community ARI attended at emergency departments. SAMPLE SIZE: 903 cases. INTERVENTIONS: Collection of cases in a unified database with the following variables: age, sex, ARI type, diagnosis of comorbidity, prescribed antimicrobial, hospital admission and type of prescriber. A panel of experts was commissioned to elaborate the gold standards for the appropriate use of antibiotics or the lack of indication for the different locations of ARI. RESULTS: The adjusted proportion of the inappropriate prescription for the group with laryngo-tracheal-influenza-rhinopharyngitis-multiple ARI or non specified infections was 67.9%. CONCLUSIONS: Concerning antibiotic prescription, significant inter-center variability and relevant heterogeneity were observed.


Asunto(s)
Antibacterianos/uso terapéutico , Prescripciones de Medicamentos , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Enfermedad Aguda , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Pacientes Internos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores Sexuales , España
19.
Rev. clín. esp. (Ed. impr.) ; 211(supl.1): 2-7, mar. 2011. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-87976

RESUMEN

La población de 65 años o más se incrementará en las próximas décadas, sobre todo en España y resto de Europa. Las enfermedades cardiovasculares (ECV) representan la principal causa de morbilidad y mortalidad en el mundo y también en nuestro país. La mayoría de estudios realizados sobre factores de riesgo vascular (FRV) se han hecho en personas más jóvenes, en general de menos de 70 años y sin otras condiciones patológicas asociadas. Los pacientes pluripatológicos son personas con múltiples patologías crónicas y edad avanzada, media de edad de 78 años, en los que las enfermedades más determinantes son las cardiovasculares, presentando varios FRV y ECV, con una elevada mortalidad. Hay que diseñar estrategias que disminuyan la morbimortalidad también en este grupo de edad(AU)


The population aged 65 years or more is set to increase in the next few years, especially in Spain and elsewhere in Europe. Cardiovascular diseases (CVD) are the main cause of morbidity and mortality worldwide as well as in Spain. Most studies on vascular risk factors (VRF) have been performed in younger persons, usually aged less than 70 years and without associated pathologic conditions. Patients with pluripathologies are those with multiple chronic diseases and advanced age (a mean of 78 years) in whom the most significant diseases are cardiovascular, with several VRF, leading to high mortality. Strategies to reduce morbidity and mortality in this age group are required(AU)


Asunto(s)
Masculino , Femenino , Anciano , Anciano de 80 o más Años , Humanos , Enfermedades Cardiovasculares/prevención & control , Factores de Riesgo , Enfermedad de Moyamoya/epidemiología , Enfermedad de Moyamoya/prevención & control , Indicadores de Morbimortalidad , Envejecimiento/inmunología , Insuficiencia Cardíaca/prevención & control , Análisis Multivariante
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA